Raymond James on Maze Therapeutics (MAZE): 'Sell-off on HORIZON Update Looks Like an Overreaction'
Tweet Send to a Friend
Raymond James analyst Martin Auster reiterated a Strong Buy rating and $56.00 price target on Maze Therapeutics (NASDAQ: MAZE).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
